Real-world outcomes of anti-VEGF therapy in treatment-na&#xEF;ve neovascular age-related macular degeneration diagnosed on OCT angiography: the REVEAL study

Macular Diseases

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Ophthalmol Retina.

Keenan TD, Vitale S, Agrón E, Domalpally A, Antoszyk AN, Elman MJ, Clemons TE, Chew EY, Age-Related Eye Disease Study 2 Research Group.

doi: 10.1016/j.oret.2019.06.001.

Macular Diseases

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Ophthalmol Retina.

Ciulla TA, Hussain RM, Pollack JS, Williams DF

doi: 10.1016/j.oret.2019.05.017.

Macular Diseases

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Ophthalmology.

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA

doi: 10.1016/j.ophtha.2017.10.010.

COMMENTED

Macular Diseases

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems

★ 2 Recommended and commented by Prof. Dr Stephan Michels, Faculty Member

BMC Ophthalmol.

Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Sakamoto T, Wong TY, Pantiri K, Carrasco J

doi: 10.1186/s12886-020-01554-2.

Macular Diseases

SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

Ophthalmol Retina.

Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A

doi: 10.1016/j.oret.2019.09.009.

COMMENTED

Macular DiseasesRetinal Diseases

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina.

Vazquez-Alfageme C, Nicholson L, Hamilton RD, Patel PJ

doi: 10.1097/IAE.

Macular Diseases

Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies

Adv Ther.

Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J

doi: 10.1007/s12325-019-01147-6.

Macular DiseasesRetinal Diseases

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

Br J Ophthalmol.

Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group

doi: 10.1136/bjophthalmol-

Macular Diseases

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study

Retina.

Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, Wykrota H, Sharma S, Dunger-Baldauf C, Lacey S, Macfadden W, Mitchell P

doi: 10.1097/IAE.0000000000002670.

Related content

Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 19

Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry

Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems

SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies

One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration

RANIBIZUMAB TREATMENT IN TREATMENT-NAIVE NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Results From LUMINOUS, a Global Real-World Study